Targeted therapy is widely used in cancer treatment because of its minimal side effects compared to other strategies, so new targets for EC treatment are urgently needed.
The Notch signaling pathway is implicated in self-renewal of stem cells, cell-fate determination of progenitor cells and terminal differentiation of proliferating cells. 8 Notch family receptors, including NOTCH1, NOTCH2, NOTCH3 and NOTCH4, are type I transmembrane proteins with extracellular EGF-like repeats. 9 DLL1, DLL3, DLL4, JAG1 and JAG2 with Delta/Serrate/LAG-2 (DSL) domain are typical Notch ligands. 8 Notch-ligand binding induces the cleavage of Notch receptor by metalloprotease and γ-secretase to release Notch intracellular domain (NICD), then translocates into the nucleus to associate with DSL transcription factor which mediates gene transcription. 5 Notch signaling is oncogenic in a variety of human tumors, such as through chromosomal translocation of NOTCH1 in acute lymphoblastic leukemia, 10 amplification and overexpression of NOTCH2 in medulloblastoma, 11 and amplification and overexpression of NOTCH3 in ovarian cancer. 12 The gene mutation of Notch pathways, including NOTCH2, is reported to be involved in EC. 13, 14 A notably higher NOTCH2 expression level was found in esophageal squamous cell carcinoma (ESCC) tissues, and its overexpression was significantly associated with worse overall survival and progression-free survival rates in ESCC patients. 15 In this study, the function of NOTCH2 in EC cells was extensively elucidated, and deltex E3 ubiquitin ligase 3 (DTX3) was identified as a novel E3 ligase for NOTCH2 and promoted its degradation, revealing a potential therapeutic target for EC.
| MATERIAL S AND ME THODS

| Plasmid construction
The shRNA for NOTCH2 and DTX3 were synthesized as oligos (Sangon), annealed and inserted into the pLKO.1 vector that was digested with EcoRI and AgeI, the specific sequence for shRNA (see Table   S1 ). The shRNA2 for NOTCH2/DTX3 were designed and targeted for the 3′-UTR sequence. The plasmids of pCDH, pCDH-NOTCH2, pCDH-DTX3-Flag, pDEST32-NOTCH2 and pDEST22-DTX3 were kindly provided by Professor Ronggui Hu (Chinese Academy of Sciences, Shanghai, China). The plasmid of pCDH-DTX3-Flag (ΔRING) was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
| Cell culture, transfection and treatment
The normal human esophageal epithelial cell line (HEEC) and human esophageal carcinoma cell lines KYSE150, TE-1 and Eca-109 were cultured in RPMI-1640 medium, supplemented with 10% FBS and 100 U/mL penicillin and 100 mg/mL streptomycin (all from Gibco), in a 37°C humidified atmosphere of 5% CO 2 . The plasmids contained NOTCH2/DTX3 shRNA or DTX3 were transiently transfected into human esophageal carcinoma cells using Lipofectamine 2000 (Life Technologies) according to the manufacturer's instructions and the stably transfected cell lines were screened by puromycin (2 μg/μL, Thermofisher). For bortezomib (BTZ), bafilomycin (BAF) or cycloheximide (CHX) treatments, cells were treated with BTZ (1 μmol/L), BAF (2 μmol/L) or CHX (100 μg/mL) for 6-8 hours before harvested, then subjected to immunoblotting analysis.
| Quantitative RT-PCR
Total RNA were extracted from cells using a Total RNA Kit (Tiangen).
Complementary DNA (cDNA) was synthesized using ReverTra Ace qPCR RT Master Mix (Toyobo). Quantitative PCR (qPCR) assay was performed to assess the relative abundances of NOTCH2 and GAPDH mRNA using specific primers (Table S2) , stained by SYBR Green (Toyobo) on the ABI 7500 Fast Real-Time PCR System (ABI).
The relative abundances of NOTCH2 were normalized to that of GAPDH gene expression, using the ΔΔ Ct method. 16 All data were obtained from three independent experiments.
| Yeast two-hybrid screen
The GAL4-based yeast two-hybrid system (Y2H, Invitrogen) was used to screen for and analyze the protein-protein interaction in yeast. 16 The plasmid pDEST32-NOTCH2 containing the in-frame fusion of GAL4 DNA binding domain acted as a bait. The prey vector pDEST22 containing human cDNA collections in-frame fused to the GAL4 activating domain (Invitrogen). Using the empty pDEST22 plasmid as a negative prey control, Y2H screening was performed by transforming yeast strain (Mav203 strain) containing pDEST32-NOTCH2 with the prey vectors for the human E3 cDNA expression library. Yeast transformants were first grown on the agar plate on SD-2 (deficient in Leu, Trp) for selection of yeast cells containing both bait and prey vectors, and then transferred to SD-4 (deficient in Leu, Trp, His and Ura) plates to screen for proteins that potentially interact with human NOTCH2. Colonies grown on the SD-4 plates were picked and streaked onto another SD-4 plate with X-Gal (5-bromo-4-chloro-3-indolyl-beta-d-galactopyra-noside, Sigma) added. "Positive" colonies were sequenced after amplification in Escherichia coli. Each interaction was confirmed by transforming yeast Mav203 cells with the indicated bait and prey vectors, and allowing the transformants to grow on the SD-2 or SD-4 agar plates (with or without X-Gal) for approximately 3 days at 30°C. Images of the colonies on both plates were recorded.
| Cell proliferation assay
A total of 3000 cells that stably transfected with the plasmids of pLKO.1-Scramble/pLKO.1-NOTCH2-shRNA or pCDH/pCDH-NOTCH2/pCDH-DTX3 were seeded into a 96-well-plate. Six hours after cell seeding was defined as the 0-hour time point; 0, 24, 48 or 72 hours later, the cells were incubated with CCK-8 solution (C0037, Beyotime Biotechnology) for 2 hours at 37°C; then the absorbance of cells was quantified spectrophotometrically at a wavelength of 450 nm using a Microplate Reader (Bio-rad).
Experiments were finished in six replicates and repeated three times.
| Colony formation assay
One thousand cells that stably transfected with the plasmids of pLKO.1-Scramble/pLKO.1-NOTCH2-shRNA or pCDH/ pCDH-NOTCH2/pCDH-DTX3 were seeded into 6-well-plates.
Seven days later, plates were fixed with 4% paraformaldehyde (Sigma) and stained with 0.1% crystal violet (C0121, Beyotime Biotechnology); then the colony number was counted.
| Wound-healing assay
Cells were plated into 6-well plates at 10 5 cells/well and 100-mL tips were used to scratch the monolayer of cells when they grew to 90% confluence in each well. Then, the plates were washed by PBS twice and filled with fresh medium for 12 hours. Images of cells migrating at the wound sites were captured using an inverted microscope (IX51, Olympus). 
| Co-immunoprecipitation, immunoprecipitation and immunoblotting
| Immunofluorescence
Cells were fixed in 4% paraformaldehyde, and incubated with anti-NOTCH2 or anti-DTX3 antibodies, followed by staining with dye-conjugated secondary antibodies and DAPI, as described previously. 17 Images were taken by fluorescence microscope (BX51, Olympus) using an oil lens (100×).
| Tumor xenograft assay
Five-week-old athymic female nude mice were purchased from the Shanghai Laboratory Animal Centre (SLAC). All animal studies were performed with approval from the Animal Care and Use
Committee of Shanghai Changzheng Hospital, Second Military
Medical University. Eca-109 cells that stably expressed. pPCDH or pCDH-DTX3-Flag were injected subcutaneously (1 × 10 7 cells/ mouse) into the mice, with six mice each group. The volume of tumors was measured with a vernier caliper every 3 days. Mice were killed 21 days later, and the weights of tumors were measured.
| Immunohistochemistry
Human EC tissue arrays were purchased from Shanghai Outdo Biotech. Immunohistochemistry for tissues from mice or patients with EC was performed as previously reported. 16 Briefly, tissues were fixed in formalin, embedded in paraffin and sectioned before being mounted on slides, which were then subjected to deparaffinization and rehydration. Then, the slides were microwaved for 30 minutes in 0.01 mol/L sodium citrate buffer (PH 6.0). After antigen retrieval and pre-incubation with 10% normal goat serum, anti- for each photograph. The density was counted using Image-Pro Plus 6.0 software (Media Cybernetics). A uniform setting for all the slides was applied for the reading of each antibody staining. The integrated optical density of all the positive staining in each photograph was measured, and its ratio to total area of each photograph was calculated as the density. 18 
| Nuclear and cytoplasmic extract
The nuclear and cytoplasmic extracts were prepared from Eca-109 cells using a Nuclear and Cytoplasmic Protein Extraction Kit (P0027, Beyotime Biotechnology) according to the manufacturer's instructions.
| Statistical analysis
The data were analyzed by two-tailed Student's t test or one-way ANOVA when appropriate. *P < 0.05 was considered a significant difference and **P < 0.01 was considered a very significant difference.
All statistical analyses were performed using the SPSS 17.0 statistical software (SPSS) or the GraphPad Prism 5 software (GraphPad Software).
| RE SULTS
| Higher expression of NOTCH2 in human esophageal carcinoma cells
To explore the expression profile of NOTCH2 in human esophageal carcinoma cells, lysates of three human esophageal carcinoma cell lines (KYSE150, TE-1 and Eca-109) and one normal HEEC were prepared. Immunoblotting analysis indicated that the protein levels of NOTCH2 were significantly higher in the three human esophageal carcinoma cell lines compared to the normal cell line, and this was consistent with the mRNA levels of NOTCH2 detected by quantitative RT-PCR (qRT-PCR) ( Figure 1A ). These results suggest higher NOTCH2expression in human esophageal carcinoma cells.
| Ablation of NOTCH2 inhibits the proliferation and migration of human esophageal carcinoma cells
To explore the effect of NOTCH2 on the proliferation of esophageal carcinoma cells, shRNA for NOTCH2 were designed and tested in two esophageal carcinoma cell lines (TE-1 and Eca-109).
Immunoblotting analysis indicated that NOTCH2 significantly decreased in cells stably transfected with shRNA compared to Scramble groups. Cell viability were detected by CCK-8 assay at 24, 48 and 72 hours post-culture, and obvious cell growth arrest was observed in NOTCH2 knockdown cell lines compared to control groups, while reintroduction of NOTCH2 led to a reverse of this change ( Figure 1B ). Next, colony formation assay was performed.
Significantly decreased colony numbers were found in NOTCH2
knockdown groups compared to control groups both in TE-1 and Eca-109 cell lines, while reintroduction of NOTCH2 could reverse this phenomenon ( Figure 1C ). Then, the wound-healing assay indicated that NOTCH2 knockdown cells maintained longer widths 12 hours after scratching as compared to the control groups which exhibited much smaller widths, while reintroduction of NOTCH2 led to a reverse of this change, implying a poorer migration ability of cells with NOTCH2 knockdown ( Figure 1D ). These data suggest that ablation of NOTCH2 inhibited the proliferation and migration of human esophageal carcinoma cells.
| NOTCH2 is a novel substrate for E3 ligase DTX3
The endogenous NOTCH2 protein was increased upon treatment with the proteasomal inhibitor BTZ, but not the autophagy inhibitor Bafilomycin A1 (BAF) in Eca-109 cells, suggesting that endogenous NOTCH2 protein undergoes proteasome-dependent degradation, rather than autophagy pathway (Figure 2A ). Yeast twohybrid (Y2H) screening was performed to identify the potential E3 ligase for NOTCH2. DTX3 was identified and validated in yeast cells F I G U R E 1 Ablation of NOTCH2 inhibits the proliferation and migration of human esophageal carcinoma cells. A, The mRNA and protein profile of NOTCH2 in normal human esophageal epithelial cell line and human esophageal carcinoma cell lines detected by quantitative RT-PCR and immunoblotting. KYSE150, TE-1 and Eca-109, human esophageal carcinoma cell lines. Data expressed as mean ± SD and analyzed using one-way ANOVA with Tukey's post-hoc test. *P < 0.05, significant difference; **P < 0.01, very significant difference; three independent experiments. B, NOTCH2 knockdown inhibits the proliferation of TE-1 and Eca-109 cells. The knockdown efficiency of shRNA for NOTCH2 was detected by immunoblotting. TE-1 and Eca-109 cells that stably expressed NOTCH2 shRNA, as well as NOTCH2 reintroduced cells, were seeded into 96-well plates and detected by CCK-8 assay at indicated time points. Six hours after cells seeded was taken as the 0-h time point. Data are expressed as mean ± SD and analyzed using two-tailed unpaired t test. *P < 0.05, significant difference; **P < 0.01, very significant difference; three independent experiments. C, NOTCH2 knockdown inhibited the colony formation of TE-1 and Eca-109 cells. TE-1 and Eca-109 cells that stably expressed Scramble or NOTCH2 shRNA, as well as NOTCH2 reintroduced cells, were seeded into 6-well-plates. Colonies were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet 7 d later. The colony number was counted, with three samples in each group. Data expressed as mean ± SD and analyzed using two-tailed unpaired t test. *P < 0.05, significant difference; **P < 0.01, very significant difference; three independent experiments. D, NOTCH2 knockdown inhibited the migration of TE-1 and Eca-109 cells detected by wound-healing assay. TE-1 and Eca-109 cells that stably expressed Scramble or NOTCH2 shRNAs, as well as NOTCH2 reintroduced cells, were seeded into 6-well-plates and a wound-healing assay was done. The images were taken at 0 and 12 h, respectively (40×) Figure 2B ). Co-IP analysis showed that endogenous NOTCH2 could form a complex with endogenous DTX3 and DTX3L, but could not form a complex with DTX1, DTX2 and DTX4 in Eca-109 cells ( Figure 2C ).
Immunofluorescence assay indicated that NOTCH2 and DTX3 were co-localized in the cytoplasm of human Eca-109 cells ( Figure 2D ). The nuclear and cytoplasmic extracts were prepared from Eca-109 cells.
Immunoblotting analysis indicated that NOTCH2 was localized in the cytoplasm, while DTX3 could be detected in the nucleus and the cytoplasm, but was mainly localized in the nucleus (Figure 2E ). Further immunoprecipitation analysis demonstrated that DTX3 overexpression increased the ubiquitination of NOTCH2 in Eca-109 cells ( Figure 2F ).
Altogether, our results indicated that DTX3 interacted with and ubiquitinated NOTCH2.
| DTX3 promotes the degradation of NOTCH2
With the degradation of NOTCH2 protein in a proteasome-dependent manner (Figure 2A) , we explored the effect of DTX3 on the stability of NOTCH2 protein. Immunoblotting analysis indicated that NOTCH2 significantly decreased in DTX3 overexpression groups compared to control groups both in TE-1 and Eca-109 cell lines ( Figure 3A) . The gene expression of NOTCH2 was detected by qRT-PCR, and we found no significant mRNA level changes in the two groups ( Figure 3B ). Further study indicated that DTX3 degraded the NOTCH2 protein in a dose-dependent manner ( Figure 3C ). The ablation of DTX3 by shRNA inhibited the degradation of NOTCH2, while reintroducion of DTX3 could rescue the protein levels of NOTCH2 ( Figure 3D ). Then our study found that proteasomal inhibitor BTZ could prevent the DTX3mediated degradation of NOTCH2 protein ( Figure 3E ), and degradation of NOTCH2 by DTX3 depends on its E3 ligase activity ( Figure 3F ). 
| DTX3 inhibits the proliferation of human esophageal carcinoma cells
| DTX3 suppresses the tumorigenicity of human esophageal carcinoma cells in nude mice
A tumorigenicity model in nude mice was used to further probe the effect of DTX3 on human esophageal carcinoma cells. Eca-109 cells that stably transfected with pCDH or pCDH-DTX3
were injected into nude mice. The tumors of the pCDH group grew quickly compared to the pCDH-DTX3 group, and the tumors in the PCDH group were significantly heavier than in the pCDH-DTX3 group (Figure 5A,B) . Immunohistochemistry showed that the protein level of NOTCH2 was lower in the pCDH-DTX3 group compared to the pCDH group ( Figure 5C ). Figure 5D ). Immunohistochemistry showed that proliferationassociated marker molecules Ki-67 and PCNA were lightly stained in the pCDH-DTX3 group compared to the pCDH group ( Figure 5E ).
F I G U R E 2 DTX3 interacted and ubiquitylated NOTCH2. A, Endogenous NOTCH2 primarily undergoes proteasome-dependent degradation. BAF, bafilomycin, an autophagy inhibitor; BTZ, bortezomib, a proteasome inhibitor. Before harvest, Eca-109 cells were treated with BTZ (1 μmol/L) or BAF (20 nmol/L) for 6 h. B, Yeast two-hybrid (Y2H) screening identified DTX3 as an interacting partner for NOTCH2. NOTCH2 was used as a bait. SD-2, deficient in Leu and Trp; SD-4, deficient in Ura, His, Leu and Trp. C, Endogenous DTX3 and NOTCH2 form a complex in Eca-109 cells, as demonstrated by a Co-IP assay using anti-IgG or anti-NOTCH2, followed by immunoblotting with anti-DTX3 or anti-NOTCH2 antibodies. The interaction of NOTCH2 with other DTX family number was also detected with the specific antibodies indicated. D, DTX3 co-localized with NOTCH2 in Eca-109 cells. Eca-109 cells were fixed with 4% paraformaldehyde, and immunostained with DTX3 and NOTCH2 antibodies; images were taken by Olympus BX51 using an oil lens (100×). E, Immunoblotting analysis of cytoplasmic and nuclear fractions was done in Eca-109 cells using indicated antibodies. β-Tubulin is the internal control for the cytoplasm, and LMNB1 is the internal control for the nucleus. F, DTX3 promotes the ubiquitination of endogenous NOTCH2. The lysates of Eca-109 cells that stably expressed pCDH or pCDH-DTX3 were immunoprecipitated with anti-NOTCH2 antibody and subjected to immunoblotting analysis using anti-UB or anti-NOTCH2 antibody promotes the degradation of endogenous NOTCH2. The lysates of TE-1 and Eca-109 cells that stably expressed PCDH or PCDH-DTX3 were subjected to immunoblotting analysis using anti-DTX3 or anti-NOTCH2 antibody. B, DTX3 has no obvious effect on the expression of NOTCH2 mRNA in TE-1 and Eca-109 cells. The total RNA of TE-1 and Eca-109 cells that stably expressed pCDH or pCDH-DTX3 were separated and subjected to quantitative RT-PCR analysis. Data expressed as mean ± SD and analyzed using two-tailed unpaired t test. NS, no significant difference; three independent experiments. C, DTX3 promotes the degradation of NOTCH2 in a dose-dependent manner. Eca-109 cells that were transiently transfected with different amounts of PCDH-DTX3-Flag were subjected to immunoblotting analysis using anti-NOTCH2, anti-Flag, anti-NICH or anti-GAPDH antibody. NICH, notch intracellular domain. D, DTX3-knockdown inhibits the degradation of NOTCH2, while reintroducion of DTX3 could rescue the protein levels of NOTCH2. Eca-109 cells were stably transfected with Scramble or DTX3 shRNA, and DTX3 was reintroduced in shRNA2 stably expressed cell lines. This experiment was repeated three times and the protein levels of NOTCH2 were quantitated. *P < 0.05, significant difference; **P < 0.01, very significant difference. E, Detect the effect of proteasomal inhibitor bortezomib (BTZ) and protein translation inhibitor cycloheximide (CHX) on the reduction of NOTCH2 by DTX3. Eca-109 cells transfected with pCDH or pCDH-DTX3-Flag were treated with CHX (100 μg/mL) at indicated duration or treated with BTZ (1 μmol/L) for 6 h. CHX, cycloheximide. F, The E3 ligase activity of DTX3 is required for the reduction of NOTCH2. Eca-109 cells transfected with pCDH, pCDH-DTX3-Flag or pCDH-DTX3-Flag (ΔRING) were treated with CHX (100 μg/mL) at indicated duration. This experiment was repeated three times and the protein levels of NOTCH2 were quantitated. *P < 0.05, significant difference; **P < 0.01, very significant difference 
| The low expression of NOTCH2 while high expression of DTX3 is beneficial to patients with esophageal cancer
Tissues from patients with human EC were immunostained with anti-NOTCH2 or anti-DTX3 antibody, respectively. The expression of NOTCH2 was higher in cancers compared to adjacent tissues (Figure 6A,B) . However, immunohistochemistry showed that the protein levels of DTX3 were lower in cancers compared to adjacent tissues ( Figure 6C,D) . Correlation analysis revealed that the expression of DTX3 and NOTCH2 had a significant negative correlation in human EC samples ( Figure 6E ). 
| D ISCUSS I ON
The Notch signaling pathway has been extensively studied and is involved in many biology functions, such as cell proliferation, differentiation, apoptosis, adhesion, embryonic development, angiogenesis and tumor formation. 19, 20 Mammalian Notch receptors include NOTCH1, NOTCH2, NOTCH3 and NOTCH4. 8 NOTCH2 plays an important role in the development of various tumors, it can promote the proliferation of hepatocellular carcinoma and reduce the sensitivity of tumors to 5-fluorouracil. 21 study Liu et al (2016) reported that high Notch2 mRNA expression predicted better overall survival in lung adenocarcinoma. 22 However, in our study, we found that low expression of NOTCH2 is beneficial to patients with EC. Wang's study found a notably higher NOTCH2 expression level in ESCC tissues, and its overexpression was significantly associated with worse overall survival and progressionfree survival rates in ESCC patients. 15 Whether NOTCH2 acts as an anti-oncogene or oncogene might depend on the cancer type. The DTX protein family has been reported to be involved in the Notch signaling pathway, and human DTX1 includes a basic N terminus, which binds the ankyrin repeats of intracellular Notch. [23] [24] [25] In the fly, DTX augments Notch signals that are dependent on the downstream transcription factor Su (H). 26 The ectopic DTX perturbs myogenesis, neurogenesis and lymphogenesis, and alters the transcriptional activity of E2A in mammalian systems. [27] [28] [29] In our study, overexpression of DTX3 in human esophageal carcinoma cells inhibits its proliferation.
The ubiquitin-proteasome pathway plays an important role in biological function. 16 DTX3 contains a typical RING-type E3 ubiquitin ligase domain 23 and no substrate has been reported before. In our study, DTX3 was identified as a novel E3 ligase for NOTCH2, and promoted its degradation. The protein expression of DTX3 and NOTCH2 is negatively correlated in patients with EC.
In summary, our study suggested that the DTX3-NOTCH2 axis plays an important role in the progression of EC, and DTX3 acts as an anti-oncogene in esophageal carcinoma, which might offer a potential therapeutic target for EC. An ongoing goal in our studies is to develop drugs that activate DTX3, and we believe that activating the expression of DTX3 might be a good approach for anticancer therapy.
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